Franklin Resources Inc. Has $38.36 Million Stock Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Franklin Resources Inc. increased its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 99.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,302,546 shares of the company's stock after acquiring an additional 1,145,823 shares during the quarter. Franklin Resources Inc. owned about 1.75% of Centessa Pharmaceuticals worth $38,360,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CNTA. First Light Asset Management LLC lifted its position in shares of Centessa Pharmaceuticals by 59.2% during the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company's stock worth $43,168,000 after purchasing an additional 1,778,515 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in shares of Centessa Pharmaceuticals by 27.6% during the second quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company's stock worth $35,518,000 after buying an additional 850,000 shares during the last quarter. FMR LLC boosted its position in shares of Centessa Pharmaceuticals by 4.6% in the third quarter. FMR LLC now owns 2,916,494 shares of the company's stock valued at $46,635,000 after acquiring an additional 129,300 shares during the period. Point72 Asset Management L.P. grew its stake in shares of Centessa Pharmaceuticals by 54.1% in the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company's stock worth $43,423,000 after acquiring an additional 953,659 shares during the last quarter. Finally, Driehaus Capital Management LLC increased its position in Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company's stock worth $18,891,000 after acquiring an additional 987,997 shares during the period. Institutional investors and hedge funds own 82.01% of the company's stock.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction on Friday, September 20th. The stock was sold at an average price of $16.53, for a total value of $909,150.00. Following the transaction, the chief executive officer now owns 721,924 shares of the company's stock, valued at approximately $11,933,403.72. The trade was a 7.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Tia L. Bush sold 17,813 shares of the firm's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $18.00, for a total value of $320,634.00. Following the completion of the sale, the chief technology officer now owns 147,615 shares of the company's stock, valued at approximately $2,657,070. This trade represents a 10.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 374,642 shares of company stock worth $6,375,876 in the last quarter. 11.59% of the stock is owned by corporate insiders.

Centessa Pharmaceuticals Price Performance

Shares of CNTA traded down $1.09 during mid-day trading on Wednesday, reaching $16.51. The company had a trading volume of 578,684 shares, compared to its average volume of 432,204. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a market capitalization of $2.18 billion, a P/E ratio of -10.79 and a beta of 1.52. Centessa Pharmaceuticals plc has a twelve month low of $6.65 and a twelve month high of $18.97. The company's 50-day moving average is $16.58 and its 200-day moving average is $13.49.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. On average, equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of research reports. Guggenheim increased their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday, November 15th. Jefferies Financial Group increased their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. Morgan Stanley upgraded Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. BMO Capital Markets raised their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a research report on Monday, September 16th. Finally, B. Riley began coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a "buy" rating and a $33.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals has a consensus rating of "Buy" and an average price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.